The understanding of the immunopathology in COVID-19 infection

Basit Öğe Kaydı
dc.authoridDidem Akal Taşcıoğlu / 0000-0003-2172-2611
dc.authorscopusidDidem Akal Taşcıoğlu / 39362314000
dc.authorwosidDidem Akal Taşcıoğlu / GMU-4600-2022
dc.contributor.authorAkal Taşcıoğlu, Didem
dc.contributor.authorAkkaya, Emre
dc.contributor.authorGenc, Sema
dc.date.accessioned2021-05-28T10:38:27Z
dc.date.available2021-05-28T10:38:27Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractCoronaviruses belonging to the Coronaviridae family are single-stranded RNA viruses. The entry of SARS-CoV-2 is accomplished via ACE-2 receptors. SARS-CoV-2 infection coactivates both innate and adaptive immune responses. Although SARS-CoV-2 stimulates antibody production with a typical pattern of IgM/IgG, cellular immunity is also impaired. In severe cases, low CD4 + and CD8 + T cell counts are associated with impaired immune functions, and high neutrophil/lymphocyte ratios accompanying low lymphocyte subsets have been demonstrated. Recently, high IFN -?/? ratios with impaired T cell responses, and increased IL-1, IL-6, TNF-?, MCP-1, IP-10, IL-4, IL-10 have been reported in COVID-19 infection. Increased proinflammatory cytokines and chemokines in patients with severe COVID-19 may cause the suppression of CD4 + and CD8 + T cells and regulatory T cells, causing excessive inflammatory responses and fatal cytokine storm with tissue and organ damage. Consequently, novel therapeutics to be developed against host immune system, including blockade of cytokines (IL-6, IL-1, IFN) themselves, their receptors or signaling pathways- JAK inhibitors- could be effective as potential therapeutics.en_US
dc.identifier.citationTascioglu, D., Akkaya, E., & Genc, S. (2021). The understanding of the immunopathology in COVID-19 infection. Scandinavian journal of clinical and laboratory investigation, 1–9. Advance online publication. https://doi.org/10.1080/00365513.2021.1892817en_US
dc.identifier.doi10.1080/00365513.2021.1892817en_US
dc.identifier.endpage9en_US
dc.identifier.issn0036-5513en_US
dc.identifier.issn1502-7686en_US
dc.identifier.pmid34032527en_US
dc.identifier.scopus2-s2.0-85106524178en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.1080/00365513.2021.1892817
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1763
dc.identifier.wosWOS:000654051800001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorAkal Taşcıoğlu, Didem
dc.language.isoenen_US
dc.publisherTaylor & Francis Onlineen_US
dc.relation.ispartofScandinavian Journal of Clinical and Laboratory Investigationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCOVID-19en_US
dc.subjectChemokinesen_US
dc.subjectCytokinesen_US
dc.subjectImmunotherapyen_US
dc.subjectPandemicsen_US
dc.titleThe understanding of the immunopathology in COVID-19 infectionen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
57.pdf
Boyut:
1.33 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu